Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma

NCT01530269 is registered in ClinicalTrials.gov with Phoenix Molecular Imaging as lead sponsor.

NCT NCT01530269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01530269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma
Lead sponsor
Phoenix Molecular Imaging
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2012
Completion date
January 31, 2019
Enrollment
300 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate adenocarcinoma, prostate cancer